KENNETH E. SCHWARTZ, M.D.
Osteopathic Medicine at Virginia Ave, San Mateo, CA
License number
California G28461
Category
Osteopathic Medicine
Type
Internal Medicine
License number
California G28461
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
511 Virginia Ave, San Mateo, CA 94402
Phone
(650) 344-6116
(650) 344-6696 (Fax)
(650) 344-6696 (Fax)
Professional information
Dr. Kenneth E Schwartz, San Mateo CA - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism, Endocrinology & Metabolism
Address:
511 Virginia Ave, San Mateo 94402
(650) 344-6116 (Phone), (650) 344-6696 (Fax)
(650) 344-6116 (Phone), (650) 344-6696 (Fax)
Certifications:
Diabetes, Metabolism & Endocrinology, 1979, Internal Medicine, 1976
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Stanford University
Stanford Hosp
Los Angeles County Harbor-Ucla Medical Center
Stanford University
Stanford Hosp
Los Angeles County Harbor-Ucla Medical Center
Treatment Of Subnormal Bone Mineral Density
US Patent:
6605591, Aug 12, 2003
Filed:
Nov 10, 2000
Appl. No.:
09/710729
Inventors:
Kenneth E. Schwartz - San Mateo CA
Assignee:
Genelabs Technologies, Inc. - Redwood City CA
International Classification:
A61P 1910
US Classification:
514 2, 514808, 514 9, 514178, 514179, 530307, 530317, 435 58, 552542, 552615
Abstract:
A method of treating an individual to increase the individuals bone mineral density (BMD) is disclosed. The method includes co-administering a calcitonin-like agent and a DHEA-like agent. Also disclosed are methods for potentiating the effect of treatment with a calcitonin-like agent on BMD and for increasing BMD in an individual being treated with DHEA, e. g. , for treatment of systemic lupus erythematosus (SLE).
Treatment Of Sle With Dehydroepiandrosterone
US Patent:
6552010, Apr 22, 2003
Filed:
Nov 10, 2000
Appl. No.:
09/710754
Inventors:
Kenneth E. Schwartz - San Mateo CA
Marc J. Gurwith - Los Altos CA
Marc J. Gurwith - Los Altos CA
Assignee:
Genelabs Technologies, Inc. - Redwood City CA
International Classification:
A61K 3156
US Classification:
514177, 514170, 514171
Abstract:
This invention provides a method of treating systemic lupus erythematosus (SLE) with (DHEA) and a related pharmaceutical product.
Polysilazanes And Related Compositions, Processes And Uses
US Patent:
5322913, Jun 21, 1994
Filed:
Jun 19, 1990
Appl. No.:
7/540331
Inventors:
Yigal D. Blum - Menlo Park CA
Richard M. Laine - Palo Alto CA
Kenneth B. Schwartz - San Mateo CA
Robert M. Platz - San Mateo CA
David J. Rowcliffe - Los Altos CA
Allen L. Dodge - Newark CA
Jonathan M. McLeod - Oakland CA
Daryl L. Roberts - Fremont CA
Richard M. Laine - Palo Alto CA
Kenneth B. Schwartz - San Mateo CA
Robert M. Platz - San Mateo CA
David J. Rowcliffe - Los Altos CA
Allen L. Dodge - Newark CA
Jonathan M. McLeod - Oakland CA
Daryl L. Roberts - Fremont CA
Assignee:
SRI International - Menlo Park CA
International Classification:
C08G 7704, C08G 7760, C08G 7762, C07F 708
US Classification:
528 15
Abstract:
Silazanes and related compounds are prepared by (a) providing a precursor containing at least one Si--N bond, cleaving an Si--N bond in the precursor in the presence of hydrogen or a hydrogen donor, and reacting the cleavage product with a second cleavage product or with a compound containing an Si--H bond, an N--H bond, or both, to produce an initial silazane product having at least one newly formed Si--N bond or (b) providing one or more reactants which contain an Si--H bond and an N--H bond, and causing reaction to occur between the two bonds in the presence of a transition metal catalyst to form an initial silazane product having newly formed Si--N bonds. Further products may result from additional reaction of either type. Novel compounds, including siloxazanes and high molecular weight polysilazanes, are provided. The compounds may be pyrolyzed to yield ceramic materials such as silicon nitride, silicon carbide and silicon oxynitride.
Dhea Composition And Method
US Patent:
7045513, May 16, 2006
Filed:
Mar 16, 2000
Appl. No.:
09/526802
Inventors:
Jagdish Parasrampuria - Bridgewater NJ, US
Maxine B. Yonker - Emerald Hills CA, US
Kenneth E. Schwartz - San Mateo CA, US
Marc J. Gurwith - Los Altos CA, US
Maxine B. Yonker - Emerald Hills CA, US
Kenneth E. Schwartz - San Mateo CA, US
Marc J. Gurwith - Los Altos CA, US
Assignee:
Genelabs Technologies, Inc. - Redwood City CA
International Classification:
A61K 31/56
US Classification:
514170, 514169, 514177, 514178, 514180
Abstract:
Disclosed are improved pharmaceutical formulations comprising dehydroepiandrosterone (DHEA), enriched in selected polymorphic forms, for therapeutic applications. In one embodiment, the formulation comprises, in solid form, DHEA, at least 85% of which is present as a single polymorph selected from the form I polymorph or the form II polymorph, and at least one pharmaceutical excipient. Methods for making and using such compositions are also disclosed.
Treatment Of Subnormal Bone Mineral Density
US Patent:
7612034, Nov 3, 2009
Filed:
Dec 28, 2004
Appl. No.:
11/024557
Inventors:
Kenneth E. Schwartz - San Mateo CA, US
Assignee:
Genelabs Technologies, Inc. - Sacramento CA
International Classification:
A61K 38/00
US Classification:
514 2, 42419511
Abstract:
A method of treating an individual to increase the individual's bone mineral density (BMD) is disclosed. The method includes co-administering a calcitonin-like agent and a DHEA-like agent. Also disclosed are methods for potentiating the effect of treatment with a calcitonin-like agent on BMD and for increasing BMD in an individual being treated with DHEA, e. g. , for treatment of systemic lupus erythematosus (SLE).
Dhea Composition And Method
US Patent:
2006023, Oct 19, 2006
Filed:
Mar 21, 2006
Appl. No.:
11/387111
Inventors:
Jagdish Parasrampuria - Bedminster NJ, US
Maxine Yonker - Emerald Hills CA, US
Kenneth Schwartz - San Mateo CA, US
Marc Gurwith - Los Altos CA, US
Maxine Yonker - Emerald Hills CA, US
Kenneth Schwartz - San Mateo CA, US
Marc Gurwith - Los Altos CA, US
International Classification:
A61K 31/57
US Classification:
514177000
Abstract:
Disclosed are improved pharmaceutical formulations comprising dehydroepiandrosterone (DHEA), enriched in selected polymorphic forms, for therapeutic applications. In one embodiment, the formulation comprises, in solid form, DHEA, at least 85% of which is present as a single polymorph selected from the form I polymorph or the form II polymorph, and at least one pharmaceutical excipient. Methods for making and using such compositions are also disclosed.
Treatment Of Subnormal Bone Mineral Density
US Patent:
6854468, Feb 15, 2005
Filed:
Feb 13, 2003
Appl. No.:
10/367218
Inventors:
Kenneth E. Schwartz - San Mateo CA, US
Assignee:
Genelabs Technologies, Inc. - Redwood City CA
International Classification:
A61B019/00
US Classification:
128898
Abstract:
A method of treating an individual to increase the individual's bone mineral density (BMD) is disclosed. The method includes co-administering a calcitonin-like agent and a DHEA-like agent. Also disclosed are methods for potentiating the effect of treatment with a calcitonin-like agent on BMD and for increasing BMD in an individual being treated with DHEA, e. g. , for treatment of systemic lupus erythematosus (SLE).
Treatment Of Sle With Dehydroepiandrosterone
US Patent:
2003018, Sep 25, 2003
Filed:
Jan 8, 2003
Appl. No.:
10/340267
Inventors:
Kenneth Schwartz - San Mateo CA, US
Marc Gurwith - Los Altos CA, US
Marc Gurwith - Los Altos CA, US
Assignee:
Genelabs Technologies, Inc.
International Classification:
A61K031/57
US Classification:
514/178000
Abstract:
This invention provides a method of treating systemic lupus erythematosus (SLE) with (DHEA) and a related pharmaceutical product.